Novo Nordisk partners with Anthropic’s AI models to accelerate drug development

Collaboration Details

On Wednesday Novo Nordisk announced a collaboration with Anthropic aimed at speeding the discovery and development of new medicines using artificial intelligence.

The Danish drugmaker did not disclose any financial terms for the partnership.

Both companies said they will work together to pinpoint challenges in the drug‑development pipeline and devise AI‑driven solutions.

“Joining forces with Anthropic will supercharge our R&D organization,” Novo CEO Mike Doustdar said in a statement.

An initial project will evaluate Anthropic’s Claude Science model on selected research and development workflows where the partners expect the greatest impact.

In addition to drug discovery, Novo plans to apply Anthropic’s frontier models to strengthen software development and scale AI use across the company.

The collaboration is framed as part of Novo’s broader ambition to become the world’s most AI‑driven healthcare company.

Nova also highlighted that the partnership includes “robust data governance and human oversight” to ensure responsible AI use, echoing the company’s ethical and compliance standards.

Industry Context and Implications

Pharmaceutical firms are racing to harness AI for identifying promising experimental medicines and improving investment decisions.

Recent announcements from Bristol Myers Squibb, Eli Lilly and Roche focus on supercomputing power through deals with Nvidia.

In May, Bristol Myers Squibb signed its own agreement with Anthropic, allowing Claude to tap the company’s institutional knowledge.

Merck, Takeda and Lilly have entered AI‑centered contracts potentially worth $1 billion or more with Google Cloud, Iambic Therapeutics and Insilico Medicine.

Earlier in April, Novo Nordisk partnered with OpenAI to embed AI tools into every step of its operations, signaling a multi‑partner AI strategy.

With Anthropic, Novo envisions AI models that can “advance scientific reasoning” in R&D and support agentic software engineering.

Analysts note that large language models can produce errors, and some experts warn that industry expectations may outpace demonstrated benefits.

Concerns also exist about establishing guardrails to prevent misuse of powerful generative AI technologies.

Nevertheless, Novo’s statement suggests it believes the collaboration’s governance framework will mitigate such risks.

The partnership illustrates a broader trend of big‑pharma companies seeking specialized AI models rather than relying solely on generic cloud offerings.

By testing Claude Science on high‑impact workflows, Novo hopes to generate measurable efficiency gains that could shorten development timelines.

If successful, the approach may set a precedent for other drugmakers to integrate frontier AI models into both scientific and engineering processes.

Safety, Governance and Future Outlook

Nova’s public commitment to “robust data governance and human oversight” reflects growing regulatory scrutiny of AI in regulated industries.

The company’s emphasis on ethical standards aligns with industry‑wide calls for transparent model validation and risk management.

Future phases of the collaboration could expand beyond the initial workflow tests to broader applications such as clinical trial design or real‑world evidence analysis.

Stakeholders will likely monitor the partnership’s early results to gauge whether AI‑driven acceleration translates into faster market entry for new therapies.

Why This Matters: Novo’s alliance with Anthropic aims to accelerate drug discovery using advanced AI, potentially shortening development timelines while emphasizing responsible governance.